Cost-effectiveness of Universal Isoniazid Preventive Therapy Among HIV-infected Pregnant Women in South Africa

Overview

Journal Int J Tuberc Lung Dis

Specialty Pulmonary Medicine

Date 2019 Jan 5

PMID 30606315

Citations 16

Authors

H-Y Kim

C F Hanrahan

N Martinson

J E Golub

D W Dowdy

Affiliations

Soon will be listed here.

Abstract

Objective: To estimate the incremental cost-effectiveness of universal vs. test-directed treatment of latent tuberculous infection (LTBI) among human immunodeficiency virus (HIV) positive pregnant women in South Africa.

Methods: We compared tuberculin skin test (TST) directed isoniazid preventive therapy (IPT) (TST placement with delivery of IPT to women with positive results) against QuantiFERON-TB Gold In-Tube (QGIT) directed IPT and universal IPT using decision analysis. Costs were measured empirically in six primary care public health clinics in Matlosana, South Africa. The primary outcome was the incremental cost-effectiveness ratio, expressed in 2016 US$ per disability-adjusted life-year (DALY) averted.

Results: We estimated that 29.2 of every 1000 pregnant women would develop TB over the course of 1 year in the absence of IPT. TST-directed IPT reduced this number to 24.5 vs. 22.6 with QGIT-directed IPT and 21.0 with universal IPT. Universal IPT was estimated to cost $640/DALY averted (95% uncertainty range $44-$3146) relative to TST-directed IPT and was less costly and more effective (i.e., dominant) than QGIT-directed IPT. Cost-effectiveness was most sensitive to the probability of developing TB and LTBI prevalence.

Conclusion: Providing IPT to all eligible women can be a cost-effective strategy to prevent TB among HIV-positive pregnant women in South Africa.

Citing Articles

Health and economic impacts of Vaccae vaccination incorporating active case finding in India and South Africa: a modelling study.

Yue W, Zhai P, Mao J, Ma J, Ren W, Jiang T BMJ Public Health. 2025; 2(2):e001042.

PMID: 40018595 PMC: 11816706. DOI: 10.1136/bmjph-2024-001042.

Systematic review of the economic impact of novel Mycobacterium tuberculosis specific antigen-based skin tests for detection of TB infection compared with tuberculin skin test and interferon-gamma release assays.

Gosce L, Allel K, Hamada Y, Surkova E, Kontsevaya I, Wang T PLOS Glob Public Health. 2024; 4(10):e0003655.

PMID: 39401209 PMC: 11472927. DOI: 10.1371/journal.pgph.0003655.

Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses.

Tomeny E, Hampton T, Tran P, Rosu L, Phiri M, Haigh K Pharmacoeconomics. 2024; 42(11):1209-1236.

PMID: 39110388 PMC: 11499453. DOI: 10.1007/s40273-024-01410-x.

Comparison of QuantiFERON Gold In-Tube Versus Tuberculin Skin Tests on the Initiation of Tuberculosis Preventive Therapy Among Patients Newly Diagnosed With HIV in the North West Province of South Africa (the Teko Study): A Cluster Randomized Trial.

Jarrett B, Shearer K, Motlhaoleng K, Chon S, Letuba G, Qomfo C Clin Infect Dis. 2024; 79(3):751-760.

PMID: 39036871 PMC: 11426260. DOI: 10.1093/cid/ciae268.

Screening of household contacts for TB infection in Cote d'Ivoire.

NGuessan R, Orsot D, Ahui Brou J, Bamba N, Tchoutedjem Mefo M, Bakayoko A IJTLD Open. 2024; 1(1):20-26.

PMID: 38919407 PMC: 11189601. DOI: 10.5588/ijtldopen.23.0342.

References

Bucher H, Griffith L, Guyatt G, Sudre P, Naef M, Sendi P . Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS. 1999; 13(4):501-7. DOI: 10.1097/00002030-199903110-00009. View

Mtei L, Matee M, Herfort O, Bakari M, Horsburgh C, Waddell R . High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis. 2005; 40(10):1500-7. DOI: 10.1086/429825. View

Menzies D, Pai M, Comstock G . Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007; 146(5):340-54. DOI: 10.7326/0003-4819-146-5-200703060-00006. View

Gupta A, Nayak U, Ram M, Bhosale R, Patil S, Basavraj A . Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005. Clin Infect Dis. 2007; 45(2):241-9. DOI: 10.1086/518974. View

Golub J, Saraceni V, Cavalcante S, Pacheco A, Moulton L, King B . The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007; 21(11):1441-8. PMC: 3063947. DOI: 10.1097/QAD.0b013e328216f441. View

Shrestha R, Mugisha B, Bunnell R, Mermin J, Odeke R, Madra P . Cost-utility of tuberculosis prevention among HIV-infected adults in Kampala, Uganda. Int J Tuberc Lung Dis. 2007; 11(7):747-54. View

Raby E, Moyo M, Devendra A, Banda J, de Haas P, Ayles H . The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PLoS One. 2008; 3(6):e2489. PMC: 2409073. DOI: 10.1371/journal.pone.0002489. View

Golub J, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H . Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009; 23(5):631-6. PMC: 3063949. DOI: 10.1097/QAD.0b013e328327964f. View

Lawn S, Churchyard G . Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS. 2009; 4(4):325-33. PMC: 4233405. DOI: 10.1097/COH.0b013e32832c7d61. View

10.

Akolo C, Adetifa I, Shepperd S, Volmink J . Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010; (1):CD000171. PMC: 7043303. DOI: 10.1002/14651858.CD000171.pub3. View

11.

Wood R, Liang H, Wu H, Middelkoop K, Oni T, Rangaka M . Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int J Tuberc Lung Dis. 2010; 14(4):406-12. PMC: 2837545. View

12.

Tedla Z, Nyirenda S, Peeler C, Agizew T, Sibanda T, Motsamai O . Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana. Am J Respir Crit Care Med. 2010; 182(2):278-85. DOI: 10.1164/rccm.200911-1783OC. View

13.

Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P . Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS. 2010; 24 Suppl 5:S57-65. DOI: 10.1097/01.aids.0000391023.03037.1f. View

14.

Cattamanchi A, Smith R, Steingart K, Metcalfe J, Date A, Coleman C . Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2011; 56(3):230-8. PMC: 3383328. DOI: 10.1097/QAI.0b013e31820b07ab. View

15.

Uyei J, Coetzee D, Macinko J, Guttmacher S . Integrated delivery of HIV and tuberculosis services in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2011; 11(11):855-67. DOI: 10.1016/S1473-3099(11)70145-1. View

16.

Pho M, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler L . The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. PLoS One. 2012; 7(4):e36001. PMC: 3340407. DOI: 10.1371/journal.pone.0036001. View

17.

Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, Stevens W . The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One. 2012; 7(5):e36966. PMC: 3365041. DOI: 10.1371/journal.pone.0036966. View

18.

Pooran A, Pieterson E, Davids M, Theron G, Dheda K . What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?. PLoS One. 2013; 8(1):e54587. PMC: 3548831. DOI: 10.1371/journal.pone.0054587. View

19.

Clouse K, Pettifor A, Shearer K, Maskew M, Bassett J, Larson B . Loss to follow-up before and after delivery among women testing HIV positive during pregnancy in Johannesburg, South Africa. Trop Med Int Health. 2013; 18(4):451-60. PMC: 3600093. DOI: 10.1111/tmi.12072. View

20.

Johnson L, Mossong J, Dorrington R, Schomaker M, Hoffmann C, Keiser O . Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 2013; 10(4):e1001418. PMC: 3621664. DOI: 10.1371/journal.pmed.1001418. View